
Anthera Pharmaceuticals is a biopharmaceutical company that was founded in 2004. It is headquartered in San Jose, California.
The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its lead product, Vayanta, is a pan-pancreatic lipase inhibitor.
Anthera Pharmaceuticals has a strong research and development team that works to identify and develop new treatments for various diseases.
Product Information
Anthera Pharmaceuticals is a biopharmaceutical company that focuses on developing innovative treatments for serious diseases.
Their product pipeline includes Sollpura, a recombinant human pancreatic enzyme replacement therapy for cystic fibrosis-related diabetes.
Sollpura works by replacing the missing enzymes in the pancreas to help regulate blood sugar levels.
The company also developed P-IIIb study for Sollpura, which showed a significant improvement in glycemic control in patients with cystic fibrosis-related diabetes.
Anthera's product development process is led by experienced professionals with a strong track record of success in the biopharmaceutical industry.
Their commitment to innovation and patient care is evident in their pursuit of new treatments for serious diseases.
Leadership
Anthera Pharmaceuticals has a strong leadership team in place. Stephen Lau is the VP Business Development of Anthera Pharmaceuticals.
The leadership team plays a crucial role in the company's success. Stephen Lau is the key person responsible for driving business development at Anthera Pharmaceuticals.
Stephen Lau's experience and expertise are invaluable assets to the company.
Recommended read: PS Business Parks
Industry Information
Anthera Pharmaceuticals is a biopharmaceutical company that focuses on developing innovative treatments for inflammatory and autoimmune diseases. They have a strong presence in the industry with a portfolio of products in various stages of development.
Their expertise in inflammation and autoimmune diseases has led to the development of several promising therapies, including their lead product, blisibimod. This product has shown promising results in clinical trials, demonstrating its potential in treating autoimmune diseases.
Anthera Pharmaceuticals has established partnerships with other companies to further advance their research and development efforts, expanding their reach in the industry.
For another approach, see: Logistics in Pharmaceutical Industry
NaICS Code Meaning
The NAICS code is a six-digit number that identifies a specific industry or business.
Anthera Pharmaceuticals has multiple NAICS codes: 325412, 32541, 32, 325, and 3254.
These codes are used for classification and statistical purposes.
NAICS code 325412 specifically refers to pharmaceutical and medicine manufacturing.
SIC Code Meaning
The SIC code is a system used to classify businesses by industry. Anthera Pharmaceuticals has a SIC code of 28 and 283.
SIC codes are used to categorize businesses for statistical and regulatory purposes. They can help you understand the industry and potential competitors of a company.
A SIC code of 28 specifically identifies Anthera Pharmaceuticals as a pharmaceutical preparation manufacturer. This can be useful when researching the company or its industry.
Knowing the SIC code of a company can also help you identify its potential customers and suppliers.
News & Press Releases
In the news, the latest industry report highlights a 12% increase in demand for sustainable materials in the manufacturing sector. This shift towards eco-friendly practices is expected to continue, with companies investing heavily in research and development of new sustainable technologies.

The report also notes that the use of recycled materials has become a key differentiator for businesses looking to reduce their environmental footprint. Companies that prioritize sustainability are seeing significant cost savings and improved brand reputation.
A recent survey of industry professionals found that 75% of respondents believe that sustainability will be a major factor in business decisions within the next 5 years. This trend is being driven by changing consumer behaviors and increasing government regulations.
The adoption of Industry 4.0 technologies is also on the rise, with 60% of companies investing in automation and AI solutions to improve efficiency and reduce waste. These technologies are expected to play a key role in the industry's transition to a more sustainable future.
Take a look at this: OraSure Technologies
Questions
Anthera Pharmaceuticals, a biopharmaceutical company, was founded in 2004 by Dr. Steven E. Rossi.
The company's focus is on developing treatments for autoimmune and inflammatory diseases, such as lupus and rheumatoid arthritis.
Anthera's pipeline includes a few promising candidates, like Sollpura, a treatment for cystic fibrosis.
Sollpura works by increasing the production of digestive enzymes, which helps patients digest food more effectively.
However, Anthera has faced challenges in getting its products to market, including a failed phase III trial for its treatment, vosoritide.
Frequently Asked Questions
What happened to Anthera Pharmaceuticals?
Anthera Pharmaceuticals dropped its late-stage cystic fibrosis drug, Sollpura, due to Phase 3 trial failure. The company's shares plummeted over 80% following the announcement.
Featured Images: pexels.com


